Diabetes

Exposure to air pollutants alters the composition of gut microbiota, which increases the risk of obesity, diabetes, gastrointestinal disorders, and other chronic illnesses, according to a study published in Environment International.

Michael D. Abramoff, MD, PhD, is the Robert C. Watzke, MD Professor of ophthalmology and visual sciences at the University of Iowa Carver College of Medicine. He is also a professor of electrical and computer engineering and a professor of biomedical engineering at the University of Iowa. Abramoff’s research interests include how autonomous artificial intelligence (AI) can be used to improve the lives of patients, with a focus on autonomous AI-based diagnostic and quantification algorithms for retinal disease. He is the founder and executive chairman of IDx Technologies, which developed IDx-DR, an FDA-authorized autonomous AI diagnostic system for the detection of diabetic retinopathy and macular edema. An editor from The American Journal of Managed Care® recently conducted a question-and-answer session with Abramoff regarding the use of AI in the diagnosis of diabetic retinopathy.

The FDA granted a fast track designation to Jardiance (empagliflozin) for treatment of chronic kidney disease; a new review in the New England Journal of Medicine urges physicians to prepare for self-managed abortion complications; Alcoholics Anonymous is more effective than other common abstinence treatments.

From funding innovative research to advocating for government action to providing a support structure for our community, no other organization does more to fight type 1 diabetes (T1D) than JDRF.

Today CMS announced the Part D Senior Savings Model, allowing Medicare Part D prescription drug plans to offer plan choices that provide a range of insulins to beneficiaries, at a maximum $35 copay per 30-day supply throughout the benefit year.

This study assesses the cost-effectiveness of adding a sodium-glucose cotransporter 2 inhibitor versus switching to a glucagon-like peptide-1 receptor agonist in patients with diabetes on metformin and a dipeptidyl peptidase-4 inhibitor.

The FDA announced a new draft guidance to consider broader evaluations beyond cardiovascular outcomes trials for type 2 diabetes (T2D) medications.

The American Diabetes Association (ADA) recently created a new part of its website, the Engagement Platform, designed to track legislation of interest to consumers.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

We examine the effects of MD–Value in Prevention (MDVIP) enrollment on Medicare expenditures and utilization among fee-for-service beneficiaries with diabetes over a 5-year period.

A study on data from the Women’s Health Initiative found good metabolic health and effective weight management can minimize diabetes risk in postmenopausal women. The study, published in Menopause, the journal of The North American Menopause Society, aimed to determine the relationship between metabolic weight categories with incident diabetes in postmenopausal women aged 50 to 79 years.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

Abbott recently announced a partnership with Insulet Corporation to integrate its glucose-sensing technology with an automated insulin delivery system for patients with diabetes. Specifically, Abbott’s FreeStyle Libre system will become compatible with Insulet’s Omnipod Horizon, in an effort to “offer personalized automated insulin delivery and care for people living with diabetes.”

The FDA approved Eli Lilly’s dulaglutide (Trulicity) for the reduction of major adverse cardiovascular events in adults with type 2 diabetes (T2D), with and without established cardiovascular disease (CVD), according to a press release.

This week, top managed care stories included an additional setback for Medicaid work rules; another study finding more benefits from SGLT2 inhibitors; researchers finding unwanted end-of-life care causes stress.

The 6 finalists will pitch their innovations at Google’s campus February 27 for a chance to win up to $50,000 in in-kind services from Boston Scientific and Google.

The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors leads to cardiovascular benefits in all patients with type 2 diabetes (T2D), according to a study recently published in the Journal of the American Heart Association.

There’s not much research available comparing the Paleolithic diet to other popular nutritional plans. A new study sought to scour existing data to see the Paleolithic diet’s effect on glucose and insulin regulation. The data showed no significant impact.

The 2007 paper examined the elevated risks for cardiovascular disease and type 2 diabetes for patients who have schizophrenia or bipolar disorder.

Results showed that managing T1D becomes more intense during pregnancy and in the months that follow childbirth. This is due to the need to be even more vigilant than usual in monitoring blood glucose levels and dosing insulin, tasks the women performed mostly themselves, but which can also be performed by other healthcare professionals.

Data collected between 1995 and 2014 show prevalence and incidence of diabetes are substantially higher in First Nations people in Canada compared to other people in Ontario, according to a study published in the Canadian Medical Association Journal.

Atul Grover, MD, PhD, the executive vice president for the Association of American Medical Colleges, sat down with Representative Lauren Underwood, D-Illinois, for a conversation about her healthcare-related efforts during her first year in Congress representing people from a suburban rural district 2 hours from Chicago.

Researchers discovered a link between circadian clock disturbances in pancreatic cells and type 2 diabetes (T2D), according a study published in Proceedings of the National Academy of Sciences.

For the first time, scientists obtained high-definition images of glucagon-like peptide-1 receptors, enabling future research into treatments for type 2 diabetes, according to a study published in Nature Communications.

Jeffrey D. Dunn, PharmD, MBA, has served as vice president of clinical strategy and programs and industry relations at MagellanRx, a national pharmacy benefit manager (PBM); cofounder, senior vice president, chief clinical officer, and board member of VRx, a regional PBM; and pharmacy director of SelectHealth, part of Intermountain Healthcare. Dunn was instrumental in opening and running the VRx retail pharmacy in downtown Salt Lake City, Utah. He is a board member of Care Pharmacies Cooperative, a chain of 100 retail pharmacies. An editor from The American Journal of Managed Care® recently conducted a question-and-answer session with Dunn regarding the recent Institute for Clinical and Economic Review report on the cost-effectiveness of oral semaglutide.

Results from an analysis conducted by the Pharmacy Benefit Management Institute (PBMI) show that the use of Jardiance (empagliflozin) among employees with type 2 diabetes and cardiovascular disease can save employers around $737,000 per 10,000 covered lives each year.

Novo Nordisk announced Thursday the FDA has approved injectable semaglutide (Ozempic) for adult patients with type 2 diabetes (T2D) and known heart disease.

The implementation of the Smart Snacks in School standards in 310 public schools resulted in healthier dietary intakes among students compared with those without the standards, according to a JAMA study published January 15.